Obsidian Therapeutics (OBX) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Obsidian Therapeutics is the larger company by market cap ($756.1 million vs $734.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OBX | VSTM |
|---|---|---|
| Share price | $12.24 | $8.11 |
| Market cap | $756.10M | $734.47M |
| 1-day change | -7.27% | -1.88% |
| YTD return | — | +5.05% |
| 1-year return | — | -9.28% |
| 5-year return | — | -75.51% |
| EPS (TTM) | $-1.63 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $49.97 | $10.82 |
| 52-week low | $12.07 | $3.43 |
| Distance from 52-week high | -75.51% | -25.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +218.63% | +84.96% |
| Average volume | 367.35K | 2.25M |
| Shares outstanding | 61.77M | 90.56M |
| Employees | 87 | 102 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Obsidian Therapeutics in Health Care and Verastem in Healthcare.
About Obsidian Therapeutics
OBX stock →Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Healthcare · Biotechnology · 102 employees
OBX vs VSTM FAQ
Which is bigger, Obsidian Therapeutics or Verastem?
Obsidian Therapeutics (OBX) is larger, with a market capitalization of $756.10M compared with $734.47M for Verastem (VSTM).
Are Obsidian Therapeutics and Verastem in the same industry?
No. Obsidian Therapeutics is in the Health Care sector, while Verastem is in Healthcare.